Sep 27 |
SAGE, BIIB End Collaboration for Neurology Candidate SAGE-324
|
Sep 26 |
Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate
|
Sep 26 |
Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate
|
Sep 26 |
Biogen to end Sage deal for neuro candidate
|
Sep 26 |
Roche, Biogen kidney disease drug hits main goal in late-stage study
|
Sep 25 |
Biogen's Lupus Candidate Meets Key Goals in Phase III Study
|
Sep 24 |
Biogen stock opened higher on positive lupus readout
|
Sep 24 |
Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial
|
Sep 24 |
Biogen, UCB mark late-stage trial win for autoimmune disease therapy
|
Sep 24 |
UCB and Biogen lupus drug succeeds in Phase III, but data yet to be released
|